+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating ibuzatrelvir to determine its effectiveness and safety in treating adults and adolescents aged 12 and older who have COVID-19 but are not hospitalized. The study focuses on individuals at high risk of progressing to severe illness. Participants will be randomly assigned to receive either ibuzatrelvir or a placebo, alongside standard care as available locally, with the study lasting approximately six months. Participants will receive either ibuzatrelvir tablets or placebo tablets orally every 12 hours for five days. This is a randomized, double-blind, phase 3 study comparing the investigational drug to placebo. The study allows co-administration of locally available standard treatments. The treatment period is followed by monitoring to assess outcomes related to COVID-19 progression and symptom resolution. During the study, participants will be observed for emergency department visits, hospitalizations, mortality, symptom resolution, and viral load changes over 28 days and up to 24 weeks. Researchers will collect data on medical events, including cardiovascular, renal, and pulmonary complications, as well as Long COVID symptoms. Safety is monitored through adverse event tracking. Overall participation lasts about six months with multiple assessments during this time.

Age: 12Years +All GendersPhase 3
256 locations
N

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a noninvasive eye measurement technique called dynamic light scattering spectroscopy to detect differences between patients with and without dementia. The study aims to determine which types and stages of dementia can be identified using this method. Dementia includes various conditions such as Alzheimers disease, vascular dementia, Lewy body dementia, and others, which cause brain changes leading to memory loss and cognitive decline. The study involves an office-based procedure where patients undergo pupil dilation in one eye followed by a 5-second measurement using the dynamic light scattering device attached to a standard fundus camera. This technique measures subtle molecular changes in the retina, which is connected to the brain, to detect early signs of dementia. The study includes two groups patients diagnosed with dementia and age-matched individuals without cerebral pathology. Participants will have an ophthalmic history taken and undergo pupil dilation before the measurement. The test takes about 5 minutes, and the dilation effect lasts 2 to 3 hours. Researchers will collect and analyze data to compare measurements between groups. Safety monitoring is in place, and data confidentiality is maintained. The study is expected to enroll 50 patients and continue until recruitment is complete.

Age: 18Years +All Genders
1 location
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
E

Actively Recruiting

Researchers are evaluating the Miro3D Wound Matrix to see if it improves healing in adults with chronic diabetic foot ulcers. Diabetic foot ulcers are a common complication of diabetes that are often hard to heal despite standard treatments like wound cleaning, tissue removal, pressure reduction, and moisture control. This trial compares the healing outcomes of wounds treated with Miro3D plus standard care versus standard care alone. The study includes about 180 adults with diabetic foot ulcers that have lasted between 4 weeks and 12 months and have shown limited healing during a two-week screening. After screening, participants are randomly assigned to receive either the Miro3D Wound Matrix applied topically along with standard care or standard care alone. Standard care involves sharp debridement, use of a device to reduce pressure on the wound, and moisture-retentive dressings. Participants will attend weekly clinic visits for up to 12 weeks. During each visit, researchers will measure wound size, take photos, assess infection and pain levels using a numeric scale, and monitor for adverse events. Some sites may perform additional imaging to study tissue oxygenation and fluorescence. The main goals are to determine if Miro3D helps wounds fully close and reduces wound size better than standard care alone. Safety will be monitored throughout the study, and participants will be followed for the full 12 weeks.

Age: 18Years +All GendersPhase Not Applicable
14 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness of Miro3D Wound Matrix combined with standard wound care compared to standard care alone in treating Wagner Grade 1 diabetic foot ulcers and wound dehiscence. Sponsored by Reprise Biomedical, Inc., this prospective, randomized controlled trial aims to determine whether adding Miro3D, a three-dimensional acellular porcine-derived wound matrix, improves early wound healing and overall outcomes in an outpatient setting. The study focuses on wound area reduction and granulation tissue formation at four weeks as predictors of healing by twelve weeks. Participants will be randomized into two groups one receiving Miro3D plus standard of care SOC and the other receiving SOC alone. In the Miro3D group, the device is applied weekly for four weeks, then biweekly if needed, for up to twelve weeks. The SOC group receives usual wound care like cleansing, debridement, dressings, and offloading. If wounds remain unhealed after twelve weeks in the SOC group, participants may crossover to receive Miro3D treatment for an additional twelve weeks following the same schedule. Participants will be followed weekly for up to twelve weeks, with wound measurements, imaging, pain assessments, and quality of life evaluations at each visit. Those who heal will have confirmation visits at two and four weeks post-closure. The study will measure wound area reduction, granulation tissue, pain levels, and quality of life changes. Safety monitoring will document adverse events and device-related issues throughout, with additional observation for crossover participants. The trial aims to provide clinical evidence supporting Miro3Ds role in enhancing wound healing in diabetic patients.

Age: 18Years +All GendersPhase Not Applicable
3 locations
S

Actively Recruiting

Researchers are evaluating the performance of two blood-based diagnostic aid tests designed to detect cancer in individuals aged 45 and older who show symptoms, signs, or findings that suggest possible cancer. The study focuses on cancers originating from specific sites as outlined in the protocol, aiming to establish how well these tests identify the presence of cancer compared to standard diagnostic methods. Participants will provide a blood sample for analysis by the investigational diagnostic tests. The study includes people either undergoing diagnostic work-up for suspected cancer or those recently diagnosed with cancer who have not yet received treatment. The test results will be kept blinded from investigators, clinicians, and participants, ensuring that the investigational test does not influence clinical decisions. All analyses will be done without revealing results during the study period. During the study, participants will have blood collected and undergo standard diagnostic procedures as recommended by their doctors. The research team will gather clinical outcomes based on routine care diagnostics and pathology reports. Researchers will measure how accurately the tests detect cancer and assess various test readout distributions over an 18-month period. Participants involvement includes consenting to blood draws and allowing access to diagnostic information, with no additional interventions affecting their usual care.

Age: 45Years +All Genders
42 locations
S

Actively Recruiting

Researchers are evaluating the Miro3D Wound Matrix, a biologic wound dressing made from pig liver tissue, to help heal difficult wounds and ulcers in adults. This post-market, proof-of-concept study focuses on wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers, and surgical wound openings. The study aims to understand how well Miro3D supports healing and improves quality of life when used alongside standard wound care in outpatient settings. Participants will receive weekly applications of Miro3D to their wounds for the first four weeks, alongside usual treatments like cleaning, dressing changes, offloading, and infection management. If the wound is not fully healed after four weeks, the Miro3D application frequency changes to every two weeks until healing occurs or up to twelve weeks total. The study includes a screening phase and a twelve-week treatment phase with no washout period. Throughout the study, participants will visit the clinic weekly for wound assessments, including measurements, photographs, and depth checks, and complete questionnaires about pain and quality of life. Healing progress is tracked by measuring wound size reduction and new tissue growth. Safety is closely monitored by tracking any adverse events. Participants finish the study when their wound heals or after twelve weeks and may then return to their regular doctor for follow-up care.

Age: 18Years +All GendersPhase Not Applicable
2 locations